New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position
- PMID: 19822435
- DOI: 10.1016/j.bmc.2009.09.041
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position
Abstract
The present work aimed at exploring a series of diversely 4-arylthiourea-substituted R/S-3,4-dihydro-2,2-dimethyl-6-halo-2H-1-benzopyrans structurally related to (+/-)-cromakalim. These new compounds were examined in vitro as putative potassium channel openers (PCOs) on rat pancreatic islets (inhibition of insulin release) as well as on rat aorta rings (relaxation of aorta ring) and their activity was compared to that of the reference K(ATP) channel activators (+/-)-cromakalim, (+/-)-pinacidil, diazoxide and of previously reported cromakalim analogues. Structure-activity relationships indicated that the most pronounced inhibitory activity on the insulin secretory process was obtained with molecules bearing a strong meta- or para-electron-withdrawing group (CN or NO(2)) on the phenyl ring of the arylthiourea moiety at the 4-position of the benzopyran nucleus (compounds 12-23). Among those, R/S-6-chloro-4-(4-cyanophenylaminothiocarbonylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran (16) was found to be the most potent benzopyran-type inhibitor of insulin release ever described. Most of these original benzopyran derivatives show increased selectivity for pancreatic versus vascular tissue. Radioisotopic investigations indicated that these new compounds activated pancreatic K(ATP) channels.
Similar articles
-
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.Bioorg Med Chem. 2008 May 15;16(10):5704-19. doi: 10.1016/j.bmc.2008.03.065. Epub 2008 Mar 30. Bioorg Med Chem. 2008. PMID: 18406154
-
Modulation of the 6-position of benzopyran derivatives and inhibitory effects on the insulin releasing process.Bioorg Med Chem. 2011 Jul 1;19(13):3919-28. doi: 10.1016/j.bmc.2011.05.040. Epub 2011 May 24. Bioorg Med Chem. 2011. PMID: 21664825
-
Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl- 6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (+/-)-cromakalim.J Med Chem. 2006 Jul 27;49(15):4690-7. doi: 10.1021/jm060161z. J Med Chem. 2006. PMID: 16854075
-
Pharmacology and structure-activity relationships for KATP modulators: tissue-selective KATP openers.J Cardiovasc Pharmacol. 1994;24 Suppl 4:S12-7. J Cardiovasc Pharmacol. 1994. PMID: 7898103 Review.
-
Recent developments in the chemistry of potassium channel activators: the cromakalim analogs.Curr Med Chem. 2004 May;11(9):1213-22. doi: 10.2174/0929867043365378. Curr Med Chem. 2004. PMID: 15134515 Review.
Cited by
-
2,2-Dimethyl-3,4-dihydro-2H-1,4-benzoxazines as isosteres of 2,2-dimethylchromans acting as inhibitors of insulin release and vascular smooth muscle relaxants.Medchemcomm. 2019 Feb 12;10(3):431-438. doi: 10.1039/c8md00593a. eCollection 2019 Mar 1. Medchemcomm. 2019. PMID: 31015906 Free PMC article.
-
Direct activation of β-cell KATP channels with a novel xanthine derivative.Mol Pharmacol. 2014 Jun;85(6):858-65. doi: 10.1124/mol.114.091884. Epub 2014 Mar 19. Mol Pharmacol. 2014. PMID: 24646456 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources